-
Published19/05/2026
-
Today11/06/2026
-
Deadline30/06/2026
-
Opening of tenders30/06/2026
Utilities
- indicates text translated automatically in your browsing language
Open-House Biologics Discount Agreements 2025-24 - Ranibizumab
Note: Not all information for this procedure were successfully computed. Please consult linked documents for more details.
The aim of the participating coffers is to conclude discount agreements with all suitable pharmaceutical entrepreneurs pursuant to § 130a(8) SGB V on the active substance ranibizumab. The contract is concluded within the framework of the open-house biologics procedure of the participating cash registers: Individual negotiations on contract contents are not conducted, uniform conditions apply. The participating health insurance companies do not guarantee any exclusivity to individual contractual partners. The maximum duration of the contract is 12 months starting on 01.11.2025. The contract ends no later than 31.10.2026, regardless of the date of conclusion of the contract. Access to this open house procedure is possible at any time during the contract period. The information provided on the binding period is not relevant in this case and is solely due to the mandatory requirements of the form. All further information can be found in the participation and contract documents.
tdf-non-av
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.